Oncobiologics, Inc. (NASDAQ:ONS) Files An 8-K Entry into a Material Definitive AgreementItem 1.01.
On February 1, 2018, Oncobiologics, Inc. (the “Company”) entered into the sixth amendment to the lease for its corporate headquarters located at 7 Clarke Drive, Cranbury, NJ. Under the sixth amendment, the Company leased approximately 21,274 square feet of adjacent laboratory and office space commencing March 1, 2018 for a term of 10 years. The term of the existing lease has also been extended until February 28, 2028. Under the amendment, the Company will make additional monthly lease payments of $42,548 from March 1, 2018 through February 28, 2023, increasing to $48,930 beginning March 1, 2023 through the end of the lease.
The foregoing description of the lease amendment is qualified in its entirety by reference to the sixth amendment to the lease agreement, which is filed as Exhibit 10.1 hereto.
| Item 9.01. | Financial Statements and Exhibits. |
(d) Exhibits.
Oncobiologics, Inc. ExhibitEX-10.1 2 tv485074_ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 SIXTH AMENDMENT TO LEASE AMENDMENT TO LEASE dated February 1,…To view the full exhibit click here
About Oncobiologics, Inc. (NASDAQ:ONS)
Oncobiologics, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on identifying, developing, manufacturing and commercializing complex biosimilar therapeutics. It focuses on monoclonal antibodies (mAbs) in the disease areas of immunology and oncology. The Company’s BioSymphony Platform focuses on developing and commercializing mAb biosimilars. The Company is developing a portfolio of approximately eight mAb biosimilars. The Company has advanced two product candidates into clinical trials: ONS-3010 and ONS-1045. ONS-3010 is a Phase III-ready biosimilar to adalimumab (Humira). ONS-1045 is a Phase III-ready biosimilar to bevacizumab (Avastin). The Company has identified multiple other biosimilar product candidates, including approximately six candidates that are in preclinical development. ONS-1050 is its trastuzumab (Herceptin) biosimilar. Its other product candidates include ONS-4010, ONS-1055, ONS-3030, ONS-3035 and ONS-3040.
